IO Biotech

IO Biotech EV/EBIT

Delisted·Sep 22, 2026

The EV/EBIT (Enterprise Value to EBIT) of IO Biotech (IOBT) as of Nov 20, 2026 is -0.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.29 — a change of -3.92% (higher).

EV/EBIT

-0.28

YoY

-3.92%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of IO Biotech is 2024 -0.28 . EV/EBIT (Enterprise Value to EBIT) of IO Biotech was 2023 -0.29 . It decreases by -3.92% higher compared to the previous year.

The IO Biotech EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-2.68 USD
Jan 1, 2020
-2.62 USD
Jan 1, 2021
-0.64 USD
Jan 1, 2022
-0.37 USD
Jan 1, 2023
-0.29 USD
Jan 1, 2024
-0.28 USD
Jan 1, 2025 (e)
-0.17 USD
Jan 1, 2026 (e)
0.00 USD
The IO Biotech EV/EBIT history
YEAREV/EBITYoY
est0.00-100.00%
est-0.17-39.15%
-0.28-3.92%
-0.29-21.89%
-0.37-42.27%
-0.64-75.40%
-2.62-2.29%
-2.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

EV/EBIT (Enterprise Value to EBIT) of IO Biotech is -0.28 in 2024.

EV/EBIT (Enterprise Value to EBIT) of IO Biotech changed from -0.29 to -0.28, representing a -3.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) IO Biotech since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s IO Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IO Biotech

All Key Metrics — IO Biotech